Titre :
  • PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
Auteur : Loibl, Sibylle ; Von Minckwitz, Gunter ; Schneeweiss, Andreas A ; Paepke, Stefan S ; Lehmann, Annika A ; Rezai, Mahdi M ; Zahm, Dirk DM ; Sinn, Peter P ; Khandan, Fariba F ; Eidtmann, Holger ; Dohnal, Karel K ; Heinrichs, Clemens ; Huober, Jens J ; Pfitzner, Berit BM ; Fasching, Peter A ; Andre, Fabrice ; Lindner, Judith JL ; Sotiriou, Christos ; Dykgers, August A ; Guo, Sanxing S ; Gade, Stephan S ; Nekljudova, Valentina V ; Loi, Sherene ; Untch, Michael ; Denkert, Carsten
Informations sur la publication : Journal of clinical oncology, 32, 29, (page 3212-3220)
Statut de publication : Publié, 2014-10
Sujet CREF : Cancérologie
Médecine pathologie humaine
Sciences bio-médicales et agricoles
Mots-clés MeSH : Adult
Aged
Anthracyclines -- administration & dosage
Antibodies, Monoclonal, Humanized -- administration & dosage
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- drug therapy -- genetics -- pathology
Exons
Female
Genotype
Humans
Middle Aged
Mutation
Neoadjuvant Therapy
Phosphatidylinositol 3-Kinases -- genetics
Quinazolines -- administration & dosage
Randomized Controlled Trials as Topic
Receptor, ErbB-2 -- antagonists & inhibitors -- genetics
Taxoids -- administration & dosage
Treatment Outcome
Tumor Markers, Biological -- analysis
Langue :
  • Anglais
Identificateurs : urn:issn:0732-183X 
info:doi/10.1200/JCO.2014.55.7876
info:pii/JCO.2014.55.7876
info:pmid/25199759